Bionanotechnologies for treatment and diagnosis of Alzheimer's disease

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 5, 2011, Pages 515-518

  Moghimi, S Moein ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; NANOPARTICLE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BIOTECHNOLOGY; BLOOD BRAIN BARRIER; DRUG RESEARCH; EDITORIAL; HUMAN; NANOTECHNOLOGY; NONHUMAN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; EUROPEAN UNION; HUMANS; MICE; NANOPARTICLES; NANOTECHNOLOGY;

EID: 80053206947     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.05.001     Document Type: Editorial

References (18)

1. Querfurth H.W. Alzheimer's disease. N Engl J Med 2010, 362:329-344.
2. 2010 Alzheimer's Disease Facts and Figures Available from:. http://www.alz.org/alzheimers_disease_facts_figures.asp.
3. Nanoparticles for Therapy and Diagnosis of Alzheimer's Disease Available from:. http://www.nadproject.eu/.
4. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci 2003, 23:29-33.
5. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., et al. Clearance of amyloid-β by circulating lipoprotein receptors. Nat Med 2007, 13:1029-1031.
6. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106:1489-1499.
7. Brambilla D., Verpillot R., Taverna M., De Kimpe L., Le Droumaguet B., Nicolas J., et al. New method based on capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-beta peptide. Anal Chem 2010, 82:10083-10089.
8. 1-42 peptide. Biomaterials 2011, 3:6519-6529.
9. 1-42 peptide. Biomaterials 2011, 32:1635-1645.
10. de Boer A.G., Gaillard P.J. Drug targeting to the brain. Ann Rev Pharmacol Toxicol 2007, 47:323-355.
11. Weiss N., Miller F., Cazaubon S., Couraud P.O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta Biomemb 2009, 1788:842-857.
12. Herring A., Yasin H., Ambree O., Sachser N., Paulus W., Keyvani K. Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol 2008, 18:32-39.
13. Wu Z., Guo H., Chow N., Sallstrom J., Bell R.D., Deane R., et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer's disease. Nat Med 2005, 11:959-965.
14. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
15. Moghimi S.M., Hunter A.C. Complement monitoring of carbon nanotubes. Nat Nanotechnol 2010, 5:382.
16. Emmerling M.R., Watson M.D., Raby C.A., Spiegel K. The role of complement in Alzheimer's disease pathology. Biochim Biophys Acta 2000, 1502:158-171.
17. Moghimi S.M., Hamad I., Andresen T.L., Jørgensen K., Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006, 20:2591-2593.
18. Hamad I., Al-Hanbali O., Hunter A.C., Rutt K.J., Andresen T.L., Moghimi S.M. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010, 4:6629-6638.